首页> 美国卫生研究院文献>Cells >H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
【2h】

H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy

机译:H3K18Ac作为癌症进展的标志物和抗癌治疗的潜在目标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acetylation and deacetylation are posttranslational modifications (PTMs) which affect the regulation of chromatin structure and its remodeling. Acetylation of histone 3 at lysine placed on position 18 (H3K18Ac) plays an important role in driving progression of many types of cancer, including breast, colon, lung, hepatocellular, pancreatic, prostate, and thyroid cancer. The aim of this review is to analyze and discuss the newest findings regarding the role of H3K18Ac and acetylation of other histones in carcinogenesis. We summarize the level of H3K18Ac in different cancer cell lines and analyze its association with patients’ outcomes, including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Finally, we describe future perspectives of cancer therapeutic strategies based on H3K18 modifications.
机译:乙酰化和脱乙酰化是翻译后修饰(PTM),会影响染色质结构及其重塑的调控。放置在第18位的赖氨酸上的组蛋白3乙酰化(H3K18Ac)在驱动许多类型的癌症(包括乳腺癌,结肠癌,肺癌,肝细胞癌,胰腺癌,前列腺癌和甲状腺癌)的进展中起重要作用。这篇综述的目的是分析和讨论有关H3K18Ac和其他组蛋白乙酰化在致癌作用中的最新发现。我们总结了不同癌细胞系中H3K18Ac的水平,并分析了其与患者预后的关系,包括总生存期(OS),无进展生存期(PFS)和无疾病生存期(DFS)。最后,我们描述了基于H3K18修饰的癌症治疗策略的未来观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号